Compare PRVA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | DYN |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2021 | 2020 |
| Metric | PRVA | DYN |
|---|---|---|
| Price | $24.75 | $17.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $31.17 | ★ $37.00 |
| AVG Volume (30 Days) | 718.7K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $10.72 | N/A |
| P/E Ratio | $138.06 | ★ N/A |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.78 | $8.25 |
| 52 Week High | $26.51 | $25.00 |
| Indicator | PRVA | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 41.97 |
| Support Level | $22.63 | $16.47 |
| Resistance Level | $25.23 | $19.65 |
| Average True Range (ATR) | 0.73 | 0.98 |
| MACD | 0.13 | -0.30 |
| Stochastic Oscillator | 81.98 | 5.45 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.